In a new job - January 12, 2021
AroCell announces the appointment of a new CEO
Former CFO Anders Hultman has been appointed new CEO of the company. He is very well acquainted with the company’s strategies and plans to take the AroCell TK 210 ELISA to the next level, states the company. In addition to experience as CFO, Anders has the business acumen needed for a demanding CEO assignment. He […]
Intellectual Property - May 5, 2020
AroCell files new patent application
AroCell has announced that an international (PCT) application has been filed at the Swedish Patent Office (PRV) regarding the use of Thymidine kinase 1 (TK1) in predicting the presence of and diagnosing Mycoplasma pneumonia, and in the classification of respiratory infections. “This patent application opens up a new area for using TK1 besides oncology. We […]
Intellectual Property - February 17, 2020
AroCell patent approved in China
AroCell has announced that the patent titled “Monoclonal anti-TK1 antibodies” is granted by China National Intellectual Property Administration (CNIPA). The patent relates to AroCell’s monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. The antibodies approved in the patent is used in the AroCell TK 210 ELISA kit. “We are delighted […]
In a new job - February 14, 2020
AroCell appoints Cecilia Ahlin as Chief Medical Officer
AroCell has announced that Cecilia Ahlin joins the management team as Chief Medical Officer. Cecilia Ahlin will lead and develop AroCell’s clinical strategy with focus on getting more clinical evidence for the use of TK1 as a biomarker in cancer treatment. Still an active oncologist treating patients Ahlin has over 20 years of experience treating […]
Intellectual Property - February 10, 2020
AroCell patent granted in the US
AroCell has announced that the patent regarding the method of determining a likelihood of cancer relapse is now granted by United States Patent and Trademark Office. The patent claims the method of determining a likelihood of cancer relapse in a subject who has completed cancer tumour surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an […]
Intellectual Property - February 4, 2020
AroCell has submitted a new patent application
A patent application has been submitted regarding the use of an immunoassay of Thymidine Kinase 1 (TK1) to enable more accurate prognoses in prostate cancer patients. In the study, on which this patent application is based, TK1 protein levels were assayed with AroCell TK 210 ELISA in serum samples collected from subjects with newly diagnosed […]
